BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

LifeScience Antibody Drug Conjugates

Nuance Pharma’s Ohtuvayre NDA Accepted For Review In China For COPD Maintenance Treatment

Nuance Pharma announced that the National Medical Products Administration (NMPA) of China has officially accepted for review the New Drug Application (NDA)...

January 28, 2026 | News

Insilico Medicine Receives US FDA IND Clearance For AI Designed NLRP3 Inhibitor ISM8969 In Parkinson’s Disease

Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) paves the way for ISM8969 clinical study in the United Stat...

January 26, 2026 | News

Ellipses Pharma Limited In Licences First In Class B7H3 Targeted ADC From Innolake Biopharm Co. Ltd To Expand Global Oncology Pipeline

Ellipses Pharma Limited (“Ellipses”), a clinical-stage oncology drug development company with a pipeline of innovative programmes, announced th...

January 26, 2026 | News

Kelun Biotech Articulates Global Innovation Vision At J P Morgan Healthcare Conference

From January 12 to 15, 2026, the 44th J.P. Morgan Healthcare Conference (JPMHC) was held in San Francisco, California, USA. Dr. Ge Michael, President and C...

January 19, 2026 | News

Fresenius Kabi And TQ Therapeutics Sign Strategic Agreement To Scale T Cell Manufacturing For Cell And Gene Therapy

Fresenius Kabi, an operating company of Fresenius, and TQ Therapeutics, announced today they have entered into a strategic-development agreement under...

January 16, 2026 | News

Novartis Secures Worldwide Licence To PepLib Peptide Asset To Expand Radioligand Therapy Pipeline

Zonsen PepLib Biotech Inc. announced that it has entered into a worldwide license agreement with Novartis for an undisclosed peptide-based asset in t...

January 15, 2026 | News

Biocytogen And Acepodia Advance Dual Payload Bispecific ADC Strategy Through Option Based Licensing Pact

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), announced that the companies have entered int...

January 12, 2026 | News

Sidewinder Therapeutics Secures Multi Target ADC Licensing Agreement With Lonza

Multi-target license agreement grants Sidewinder access to Lonza's clinically validated ADC platform Sidewinder's pipeline...

January 08, 2026 | News

Sichuan Kelun Biotech Secures NMPA IND Approval For SKB105 Antibody Drug Conjugate In Advanced Solid Tumours

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that its Investigational New Drug (IND) appli...

January 07, 2026 | News

Mabwell Doses First Patient Globally In Phase II Trial Of IL 11 Antibody For Pathological Scarring

Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the Phase II clinical trial of i...

January 01, 2026 | News

Senhwa Biosciences Advances CX 5461 Into ADC Combination Trial With Enhertu Backed By US NCI

Senhwa Biosciences has announced a significant clinical milestone with its investigational drug Pidnarulex CX 5461 advancing into a Phase 1...

December 30, 2025 | News

Alphamab Oncology Secures IND Acceptance In China For JSKN033 Phase II Cervical Cancer Study

Alphamab Oncology (Stock Code: 9966.HK) announced that the IND application for a Phase II clinical study of JSKN033 (a proprietary high-concentration subcu...

December 30, 2025 | News

ABL Bio Lands Strategic 55 Million Funding Boost To Fast Track Next Wave Of Breakthrough Antibody Therapies

Secured a total of 55 million in R&D funding, including 40 million in upfront payment and 15 million in equity investment - Accelerating R&D on co...

December 29, 2025 | News

Mabwell Secures US FDA IND Clearance For Anti ST2 Antibody In COPD

Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that it has received IND clearance fr...

December 26, 2025 | News

Stay Connected